BridgeBio's Oral Infigratinib Nears FDA Decision for Achondroplasia…

Event summary

FDA accepts BridgeBio's NDA for oral infigratinib in achondroplasia with a Priority Review designation, setting a PDUFA target action date of February 4, 2027.
PROPEL 3 trial met primary and key secondary endpoints, showing a +2.10 cm/year increase in annualized height velocity (p<0.0001) and statistically significant improvements in body proportionality and arm span.
BridgeBio anticipates a U.S. launch of oral infigratinib upon approval, with plans to submit a Marketing Authorization Application (MAA) to the EMA in Q4 2026.
Oral infigratinib is the only therapeutic option in development for achondroplasia to hold Breakthrough Therapy Designation from the FDA.

The big picture

BridgeBio's progress with oral infigratinib underscores the growing focus on developing targeted therapies for rare genetic conditions. The FDA's Priority Review designation highlights the critical need for effective treatments in achondroplasia, a condition affecting approximately 55,000 people in the U.S. and EU. If approved, oral infigratinib could become a best-in-class option, potentially expanding BridgeBio's footprint in the skeletal dysplasias market.

What we're watching

Regulatory Approval: Whether the FDA will approve oral infigratinib by the February 4, 2027 PDUFA target action date, potentially making it the first and only approved oral therapy for achondroplasia.
Market Potential: The pace at which BridgeBio can commercialize oral infigratinib in the U.S. and Europe, given the significant unmet need for treatments in achondroplasia.
Clinical Efficacy: How the broader medical and functional impacts of oral infigratinib, such as improvements in sleep apnea and otitis media, will influence its adoption and market position.